<< Read Full Article
<< Read Full Article
1. Dolan Doldrums
Bristol-Myers (BMY Quote) put an end to the doleful Dolan era.
CEO Peter Dolan departed Tuesday after five years atop the New York pharmaceuticals giant. A government-appointed monitor recommended Dolan be fired for possibly breaking the law in a push to shield the company's bestselling blood thinner, Plavix, from generic competition.
Bristol shares have been under heavy pressure since this summer, when the Justice Department began investigating possible antitrust infractions in a failed settlement with drugmaker Apotex of Canada. A trial in the Apotex patent dispute is set for early next year. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,445.35 | 1,107.10 | 2,173.90 | 33.27 |
Oil *
76.71
|
|
UP
11.64
|
UP
1.45
|
UP
4.72
|
UP
0.10
|
10 Yr
3.33%
SPDR Gold
115.72
|
|
+0.11%
|
+0.13%
|
+0.22%
|
+0.30%
|
Data delayed 20 minutes |


Connect with TheStreet